Baidu
map

Biochemia Medica:血清中钙离子浓度随时间的变化?

2019-11-03 MedSci MedSci原创

本研究的目的是比较动脉肝素化血液和静脉血清中的离子钙浓度,并研究在不同时间离心和分析的血清样品中离子钙的时间依赖性变化。

本研究的目的是比较动脉肝素化血液和静脉血清中的离子钙浓度,并研究在不同时间离心和分析的血清样品中离子钙的时间依赖性变化。

研究人员穿刺后20分钟测定动脉血中游离钙(N = 25),采样30分钟后离心10分钟测定血清中游离钙(N = 25)。在采样后15分钟,30分钟和60分钟分别离心的三支试管(N = 30)中检查了采样与离心之间的时间影响,并在10分钟内进行了分析。 在采样后30分钟离心的三支试管(N = 31)中研究了离心和分析之间的时间间隔,并进行了分析:离心后0-1030-4090-100分钟。 在西门子RapidLab 348EX分析仪上测量了离子钙。 使用Wilcoxon检验和ANOVA分析检验统计学意义。 根据参考变化值(RCV)判断临床意义。。

研究发现,动脉血和血清iCa值差异无统计学意义(P = 0.274)。与30分钟离心管相比,采样后6015分钟(P = 0.005, P = 0.003);离心30-40分钟和90-100分钟,离心0-10分钟离心管差异有统计学意义(P = 0.021, P = 0.027)。在6030分钟(离心)90-1000-1030-40分钟(分析)临床观察到明显的变化。

研究表明,及时分析动脉血样和血清血样可以交互使用。为避免临床显著差异,应在血清管采样后30min内离心,离心后30min内进行分析。

原始出处:

Antonija Perović,Marina Njire Bratičević,Time-dependent variation of ionized calcium in serum samples

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1918908, encodeId=a90219189085d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu May 14 02:06:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687237, encodeId=d4d1168e2375a, content=<a href='/topic/show?id=7cfc963598b' target=_blank style='color:#2F92EE;'>#钙离子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96359, encryptionId=7cfc963598b, topicName=钙离子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30528357557, createdName=12498623m102暂无昵称, createdTime=Wed Sep 23 08:06:00 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859006, encodeId=50d8185900662, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Aug 21 11:06:00 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544611, encodeId=1d6815446117e, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Nov 05 02:06:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610081, encodeId=2ec71610081e7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 02:06:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
    2020-05-14 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1918908, encodeId=a90219189085d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu May 14 02:06:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687237, encodeId=d4d1168e2375a, content=<a href='/topic/show?id=7cfc963598b' target=_blank style='color:#2F92EE;'>#钙离子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96359, encryptionId=7cfc963598b, topicName=钙离子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30528357557, createdName=12498623m102暂无昵称, createdTime=Wed Sep 23 08:06:00 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859006, encodeId=50d8185900662, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Aug 21 11:06:00 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544611, encodeId=1d6815446117e, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Nov 05 02:06:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610081, encodeId=2ec71610081e7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 02:06:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1918908, encodeId=a90219189085d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu May 14 02:06:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687237, encodeId=d4d1168e2375a, content=<a href='/topic/show?id=7cfc963598b' target=_blank style='color:#2F92EE;'>#钙离子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96359, encryptionId=7cfc963598b, topicName=钙离子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30528357557, createdName=12498623m102暂无昵称, createdTime=Wed Sep 23 08:06:00 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859006, encodeId=50d8185900662, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Aug 21 11:06:00 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544611, encodeId=1d6815446117e, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Nov 05 02:06:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610081, encodeId=2ec71610081e7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 02:06:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
    2020-08-21 jeanqiuqiu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1918908, encodeId=a90219189085d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu May 14 02:06:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687237, encodeId=d4d1168e2375a, content=<a href='/topic/show?id=7cfc963598b' target=_blank style='color:#2F92EE;'>#钙离子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96359, encryptionId=7cfc963598b, topicName=钙离子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30528357557, createdName=12498623m102暂无昵称, createdTime=Wed Sep 23 08:06:00 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859006, encodeId=50d8185900662, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Aug 21 11:06:00 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544611, encodeId=1d6815446117e, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Nov 05 02:06:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610081, encodeId=2ec71610081e7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 02:06:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1918908, encodeId=a90219189085d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu May 14 02:06:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687237, encodeId=d4d1168e2375a, content=<a href='/topic/show?id=7cfc963598b' target=_blank style='color:#2F92EE;'>#钙离子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96359, encryptionId=7cfc963598b, topicName=钙离子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30528357557, createdName=12498623m102暂无昵称, createdTime=Wed Sep 23 08:06:00 CST 2020, time=2020-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859006, encodeId=50d8185900662, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Aug 21 11:06:00 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544611, encodeId=1d6815446117e, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Nov 05 02:06:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610081, encodeId=2ec71610081e7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 02:06:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]

相关资讯

Biochemia Medica:对健康成人血清甲状旁腺素的生物学变化进行测量

在钙代谢紊乱的调查和管理中,甲状旁腺素(PTH)的测量是必不可少的。为了评估任何检测结果的重要性,必须考虑被测物的临床决策生物变异(BV)。因此,本研究的目的是确定血清甲状旁腺激素的BV参数。

Clinica Chimica Acta:急性肾损伤患者血清总钙和电离钙与全因死亡率的关系

目前还没有流行病学研究对血清总钙和电离钙(tCa和iCa)对急性肾损伤(AKI)危重患者预后的影响进行相关研究。在此,我们评估了入院tCa和iCa浓度与这些患者全因死亡率的关系。

Blood:尿单克隆蛋白不是判定MM患者是否完全缓解的必要指标

中心点:经治疗后,sIFE转为阴性的多发性骨髓瘤患者,100%(确诊时仅血清M蛋白阳性)或98.6%(确诊时血清和尿液M蛋白均阳性)的为uIFE阴性。符合完全缓解标准单无uIFE检测结果的患者的预后与完全缓解的患者的预后相当,优于部分缓解患者的预后。摘要:多发性骨髓瘤(MM)的完全缓解(CR)的标准为免疫固定电泳血清(sIFE)和尿液(uIFE)单克隆蛋白(M-蛋白)均为阴性。但患者sIFE转阴性

血清低孕酮水平患者行IVF成功妊娠并分娩一例

患者25岁,未避孕未孕2年。因子宫输卵管碘 油造影结果显示双侧输卵管不全性阻塞,行介入复 通术。术后1年再次复查造影显示双侧输卵管通 畅。男方精液正常,在我院行2个周期人工授精助 孕未孕后转行IVF。患者卵巢功能正常,第一周期 行短效长方案,黄体期醋酸曲普瑞林(达必佳,德国 辉凌)0.1 mg降调,降调16 d后B超监测双侧卵巢 窦卵泡共7个,重组人促卵泡激素(果纳芬,默克雪 兰诺)225 U启动

血清 γ 球蛋白正常的皮肤浆细胞增多症1 例

患者男, 35 岁。右侧臀部、右侧下肢红褐色斑 块、结节8 个月。患者 8 个月前无明显诱因右侧臀 部出现钱币大红褐色斑块,瘙痒明显,搔抓后皮损面 积逐渐扩大; 曾自行外用“皮炎平”等药物治疗,病 情无好转,逐渐扩大,且相互融合,并于右侧腹股沟、 右股内侧陆续出现新皮损。病程中患者无发热、关 节肿痛,睡眠饮食尚可,二便正常,体重无明显变化。 患者既往体健,否认系统性疾病,否认食物药物过敏 史,否认

Baidu
map
Baidu
map
Baidu
map